DRP Journal

Discover Research Profit

Finance 

Emergent Health Corp (OTCMKTS:EMGE) Stock Soars 545: What’s The Buzz?

Ian Leigh , , , ,

Developer and marketer of products in Regenerative Health Space, Emergent Health Corp (OTCMKTS:EMGE) on May 4, 2023, announced the implementation of Term Sheet for a company committed underwriting of $10,000,000 with respect to planned corporate financing transactions.

Trading Data     

On Thursday, EMGE stock surged 54.33% to $0.0046 with more than 19.05 million shares, compared to volume of 4.84 million shares. The stock moved within a range of $0.0030 – 0.0046 after opening trade at $0.0032.

Emergent Health to spin out subsidiary PharmaZu to its Shareholders pursuant to an IPO underwritten by a Nationally Recognized Investment Banking Firm

It also includes private placement of securities and a planned $10 million initial public offering of Emergent subsidiary’s common stock. PharmaZu, a pure-play, e-commerce productas well as a service provider, is focused on Pet Pharmacy, Pet Community, and Pet Wellness using Influencers. PharmaZu plans on acquiring a 48-state authorized compounding pharmacy located in West Palm Beach, FL, doing about $10M a year in revenue. The raise of capital will be used for expanding PharmaZu’s business, and product offerings, as well as for acquisitions.

Jim Morrison, former L’Oral President and Emergentsfull-time CEO said that the transaction with Boustead will commence a fresh chapter for PharmaZu, maximizing value to the shareholders.

Adam Books, President of PharmaZu said that PharmaZu may disruptthe mail-order pet business as well as pet medications. Books added that it would also advance the tele-pet med environment.

Implementation of an Engagement Letter does not mean commitment by Boustead or the firm to complete any transaction. It also does not ensure the successful placement of securities of any investment vehicle.

Ian Leigh

Ian Leigh is a specialist in analyzing stocks, SEC and OTC filings, and financials of public and privately-held companies. He has played a significant role in M&A activity, consulting with publicly-held firms on acquisitions and divestitures. He also consults on valuations and branding. He lectures at major universities and teaches at specialty financial schools.